Silkworm Pupa Powder for Mild-to-Moderate Alzheimer's Disease
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether silkworm pupa powder can help slow memory loss and thinking problems in people with mild-to-moderate Alzheimer's disease. Researchers will check if it works by measuring changes in memory, thinking ability, and brain markers over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with Alzheimer's disease (confirmed by memory tests and blood or brain imaging showing amyloid and tau proteins)
- Age 50–90 years old with at least a primary school education
- Memory test score between 0–24 (mild-to-moderate cognitive decline)
- Stable on current Alzheimer's medications for at least 12 weeks, or not taking any Alzheimer's drugs yet
- Have a reliable family member or caregiver who can help during the study
- Willingness to provide blood, stool, and urine samples for testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a powder made from silkworm pupae can help improve memory and thinking in people with Alzheimer's disease. It is for people with mild to severe Alzheimer's who have clear signs of the disease in their blood or brain scans.
This trial tests whether a dietary supplement made from silkworm pupa powder can improve nutrition in people with Alzheimer's disease. It looks at weight, nutrition risk, and daily living skills over time.
This trial tests whether a supplement made from silkworm pupa powder can improve nutrition in people with Alzheimer's disease. It aims to see if this natural product can help with weight and overall health.
This trial tests whether acupuncture can improve symptoms in people with Alzheimer’s disease. You may qualify if you have memory and thinking changes consistent with Alzheimer’s and meet imaging and brain-scan score requirements.
This trial tests a special supplement combination designed to support brain energy use in people with Alzheimer's. It aims to see if the supplement can help slow cognitive decline.
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
Hear when a new Sarcopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.